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Summary: Four different homogeneous non-isotopic immunoassays for the determination of total phenytoin
in serum were evaluated and compared with a gaschromatographic.method (GC) described by W. R. Külp-
mann & M. Oellerich ((1981), J. Clin. Chem. Clin. Biochem. 19, 249-258): enzyme multiplied immunoassay
technique (EMIT), fluorescence polarization immunoassay (FPIA), nephelometric Inhibition immunoassay
(NilA) and Substrate labeled fluorescent immunoassay (SLFIA).
The between-days coefficients of Variation in the medium therapeutic ränge were 4.0% (n = 29) with EMIT,
4.6% (n = 15) with FPIA, 7.8% (n = 10) with NIIA, 2.8% (n = 12) with SLFIA and 5.7% (n = 15) with GC.
The recovery in spiked serum samples (phenytoin concentration: 11.9—99.1 / ) was 98—101% with
EMIT, 97-107% with FPIA, 102-110% with NIIA, 94-97% with SLFIA and 97-104% with GC.
All of the tested immunoassays and GC yielded comparable results. The NIIA showed a somewhat lower
correlation. In samples from an uraemic patient, however, great deviations from GC values were obtained
with EMIT (bias: +22 to +85%) NIIA (+68 to +114%) and SLFIA (+48 to +52%). Only the results of
FPIA were in good agreement with those of GC (bias: +1 to -7%).
All the immunoassays showed a cross-reaction with 5^(4-hydroxyphenyl)-5^henylhydantoin, which was most
expressed with SLFIA and NIIA. The detectability of the immunoassays was adequate to allow precise
measurements within the therapeutic ränge.
After ultrafiltration of the serum, free phenytoin was measured by EMIT, FPIA and capillary gas
chromatography. The immunoassays and capillary GC yielded comparable results, though a small positive
bias between EMIT äiid FPIA was noticeable. In a sample from an uraemic patient, however, the results of
EMIT differed by +109% from the GC value, whereas FPIA showed a bias of only -12%.
Bestimmung von Gesamt- und freiem Phenytoin im Serum mit radioaktivitätsfreien Immunoassays und Gas-
'Chromatographie1)
Zusammenfassung: Vier verschiedene homogene, radioaktivitätsfreie Immunoassays zur Bestimmung von
Gesamt-Phenytoin im Serum wurden evaluiert und mit einer von W. R. Külpmann & M. Oellerich ((1981), J.
Clin. Chem. Clin. Biochem. 19, 249-258) beschriebenen gaschromatögraphischen Methode (GC) vergli-
chen: Enzyme multiplied immunoassay technique (EMIT), fluorescence polarization immunoassay (FPIA),
nephelometric Inhibition immunoassay (NIIA) und Substrate labeled fluorescent immunoassay (SLFIA). Der
Variationslcpeffizient für die Präzision von Tag zu Tag betrug im mittleren therapeutischen Bereich: 4.0% (n
t) Parts of this study have been reported at the Gemeinsame schaft für Klinische Chemie und der österreichischen Gesell-
Jährestagung Klinische Chemie der Deutschen Gesellschaft für schaft für Laboratoriumsmedizin, Stuttgart, 22.-24. Sep-
Klinische Chemie gemeinsam mit der österreichischen Gesell- tember, 1982.
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= 29) für EMIT, 4,6% (n = 15) für FPIA, 7,8% (n = 10) für NIIA, 2,8% (n = 12) für SLFIA und 5,7% (n =
15) für GC. Die Wiederfindung von Phenytoin in aufgestockten Proben im Bereich zwischen 11,9-99,1
/ schwankte zwischen 98-101% bei EMIT, 97-107% bei FPIA, 102-110% bei NIIA, 94-97% bei
SLFIA und 97-104% bei GC. Die Ergebnisse der Phenytoinbestimmung, die bei Patientenproben mit den
verschiedenen Methoden durchgeführt wurden, wurden mit denen der GC verglichen. Insgesamt ergab sich
eine zufriedenstellende Korrelation, wenngleich die mittels NIIA erhaltenen Werte etwas weniger gut über-
einstimmten. In Proben von einem urämischen Patienten unter Phenytointherapie wurden jedoch große Ab-
weichungen zu den gaschromatographisch ermittelten Werten gefunden: EMIT: +22 bis 4-85%, NIIA: +68
bis +114%, SLFIA: +48 bis +52%. Lediglich die mittels FPIA gewonnenen Ergebnisse stimmten gut mit
denen der GC überein (Abweichungen zwischen +1 und -7%). Alle Immimoassays zeigten eine Kreüzreak-
tion mit 5-(4-Hydroxyphenyl)-5-phenylhydantoin, die am stärksten ausgeprägt war bei SLFIA und NIIA.
Innerhalb des therapeutischen Bereiches erlaubten alle Immunoassays präzise Bestimmungen.
Freies Phenytoin wurde mittels Ultrafiltration abgetrennt und mit EMIT, FPIA und Kapillargaschromato-
graphie bestimmt. Die Immunoassays und die Kapillar-GC ergaben vergleichbare Ergebnisse, wenn auch die
Werte von EMIT etwas höher lagen als die von FPIA. Die Bestimmung des freien Phenytoin bei einem
urämischen Patienten unter Phenytointherapie ergab jedoch ein Ergebnis mittels EMIT, das 109% höher lag
als der gaschromatographische Vergleichswert, während die entsprechenden Werte von GC und FPIA nur um
12% voneinander abwichen.
Introduction
Therapeutic drug monitoring of total phenytoin in
epileptic patients has been widely used in the past
few years. Most of the determinations were per-
formed by GC and EMIT. Recently several new im-
munological methods for the determination of phe-
nytoin have become commercially available. In this
study three of these newer immunological methods:
FPIA, NIIA and SLFIA were evaluated. The results
from these immunoassays were compared with those
from GC. Serum samples of an uraemic patient were
included, because the accumulation of drug metabo-
lites or endogenous compounds might be expected to
cause interferences that are not usually encountered.
In addition, the reliability of the determination of
free phenytoin by EMIT and FPIA was tested.
tions by use of the TDX Fluorescence Polarization Immunoässay
System (Abbott, Wiesbaden) (3, 4, 5). The calibration curve once
established for a reagent lot was checked in the subsequent runs
by one Standard and accepted, if the deviation from the target
value did not exceed ±5%. Usually recaiibratipn was necessary
after l month.
3. Nephelometric Inhibition immunoassay (NIIA)
Reagents were supplied by Beckman (München). The determina-
tions were perforined according to the manufacturer's instfuctions
by use of the Auto ICS Immunochemistry System (Beckman,
München) (6, 7). For each run a calibration curve was prepäred.
4. Substrate labeled fluorescent immunoassay (SLFIA)
Reagents were obtained from Miles (Miles-Ames Division,
Frankfurt). The determinations were perfonhed according to the
manufacturer's instructions by use of the Ames Fluorostat (Miles-
Ames Division, Frankfurt) (8, 9. 10). The calibration curve could
be used for at least 2 weeks for the same reagent lot. The calibra-
tion curve was checked and corrected in each run by the highest
calibration Standard, if the deviation from the target value did not
exceed 6%. Otherwise recalibration was necessary.
Material and Methods
Determinat ion of total phenytoin in serum
Immunoassays
1. Enzyme multiplied immunoassay technique (EMIT)
Reagents were purchased from E. Merck, Darmstadt. The deter-
minations were performed according to the manufacturer's in-
structions by use of the EMIT-AutoLab 5000 System (Syva-
Merck, Darmstadt), or according to an adaptation of the orginal
procedure to the Eppendorf Analyzer 5010 and Eppendorf ACP
5040 (Eppendorf, Hamburg) (2).
2. Fluorescence polarization immunoassay (FPIA)
Reagents were obtained from Abbott (Wiesbaden). The determi-
nations were performed according to the manufacturer's ihtruc-
Gaschromatographic method
Phenytoin was determined by gas chromatography according to 1.
c. (1) by use of a Hewlett Packard 5880 A gas Chromatograph
(Hewlett Packard, Frankfurt).
Determination of free phenytoin
Immunoassays
Free phenytoin was separated by Ultrafiltration using EMIT Free
Level Filters I (E. Merck, Darmstadt) and determined by EMIT
and FPIA according to the manufacturer's instructions.
Gaschromatographic method
Extrelut-l^colurnns (E. Merck, Darmstadt) were rirised with 6 ml
dichloromethane and dried by suction prior to use. Ultrafiltrates
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(200 μΐ) (see above) were spiked with 100 μΐ internal Standard (5-
(4-methylphenyl)-5-phenylhydantoin; 10 mg/1) and applied to an
Extrelut-1-column. After 10min, phenytoin was eluted by 6ml
dichloromethane. The eluate was evaporated and the dry residue
dissolved in 100 μΐ ethyl acetate for the gas Chromatographie anal-
ysis. Gas chromatography was performed by use of a fused silica
capillary column (length: 25 m; internal diameter: 0.31 mm) coat-
ed with cross-linked 5% phenylmethyl silicone (Hewlett-Packard,
Frankfurt).
Inlet: Cool on column,
Oven temperature:
Initial value: 50 °C, initial time: 0.5 min
Programme rate: 30°C/min
final value 1: 220 °C, final time 1: 0.5min
Programme rate 2: 15°C/min
final value 2: 260 °C, final time 2: 3.0min
Detector: N-FID, 300 °C
Syringe: 10 μΐ capacity, fused silica needle llcm (Hamilton,
Darmstadt); injected volume: 2 μΐ.
Control sera
EMIT antiepileptic drug control was purchased from E. Merck,
Darmstadt).
ORTHO bi-level assayed anticonvulsant/antiasthmatic control set
I or II were obtained from Ortho Diagnostics (Heidelberg).
Results
Precision
The between-days precision of the immunoassays is
shown in table 1. The coefficients of Variation for
"EMIT antiepileptic drug control" ealculated from
determinations performed in duplicate were:
SLFIA: 2.8%; EMIT: 4.0%; NIIA: 7.8%, and eal-
culated from siiigle determinations: FPIA: 4.6%.
Measuring r nge
In order to estimate the detectability of the methods
the precision in the series at low concentrations was
determined (tab. 2). All procedures allow precise
measurements below the therapeutic r nge; SLFIA
and NIIA, however, were less sensitive than the oth-
er assays. At a phenytoin concentratioii of 2.0 μπιοΐ/ΐ
the coefficient of Variation was 15.9% with EMIT
-and 7.4% with FPIA.
Accuracy
Recovery
The recovery of phenytoin by the different immu-
noassays and by GC is presented in table 3. Pheny-
toin was added to pooled drug-free human serum.
The recovery within the therapeutic r nge varied be-
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*) EMIT by use
2) GC according
Spiked value Numberof Meanx 3s3)
(μπιοΙ/1) determinations (μιηοΐ/ΐ) (μιηοΐ/ΐ)
9.9 10 9.8 0.9
2.0 9 1.7 0.8
9.9 10 8.9 0.9
2.0 10 2.1 0.5
9.9 8 9.0 1.3
9.9 10 7.2 2.4
4.0 10 3.7 1.2
of the AutoLab 5000 System.























of phenytoin by various immunoassays and GC in spiked serum samples.
EMIT1) FPIA NIIA SLFIA
?/o)3) n') (%)3) n3) (%)3) n3) (%)3) n3)
110 5 91 4 84 5
98 6 97 2
110 4 94 5
101 6 107 5
103 4 97 5
100 6 105 5
102 4 97 5
9 9 6 - - - - - -
102 5 100 4 101 5






















0 EMIT by the Eppendorf ACP 5040.
2) GC according to 1. c. (1).
3) Recovery (%) calculated from n single determinations.
Comparison of methods
Values obtained from analyses of patients' speci-
mens by EMIT, FPIA, NIIA and SLFIA were com-
pared with those from GC (tab. 4).
EMIT: A proportional error of 4% and a negligible
constant error was obtained; the mean values dif-
fered by about ± 4%.
FPIA: A proportional error of 6% and a small con-
stant error was observed; the difference between the
mean values, however, was not significant.
NIIA: The proportional error was 10%, the inter-
cept 2.5 μιηοΐ/ΐ; the Standard error of the residuals
(8.6 μπιοΐ/ΐ) was caused by the lower precision of
this method.
SLFIA: In the absence of a proportional error the
intercept was minimal and the mean values were al-
most identical.
On the whole it may be concluded that - though
differences between some immunoassays and GC
were obtained - the bias between the f es lts w uld
not be of clinical relevance f r this group of patients.
Furthermore samples from an uraemic patient treat-
ed with phenytoin were analysed. Clinical chemieal
analyses in samples from this patient yielded the fol-
lowing res lts (reference valnes in parentheses):
creatinine 988 μπιοΙ/1 (^ 115μηιό1/1),
urea 24.6mmol/l (3.3-6.7mmol/l),
uric acid 357μπΐο1/1 (20CH420 μιηοΐ/ΐ),
cholesterol 5.4mmol/I (^ 7.2mia l/l),
triglycerides 2.02mmol/l (^ 1.80mmol/l),
protein 65 g/l (65-80 g/l),
albumin 40 g/l (37-51 g/l),
alanine aminotransferase 10 U/l (^ 22 U/l),
aspartate aminotransferase 8 U/l (^ 18 U/l),
alkaline phosphatase 138 U/l (76-190 U/l),
γ-glutamyltfansferase 37 U/l (^ 28 U/l),
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Tab. 4. Comparison of the results obtained by various immunoassays and GC for determination of phenytoin in samples from patients





































































*) n: Number of contributing pairs of results.
2) sy.x: Standard error of residues.3) y: Mean value of method y.
4) x: Mean value of method x.
s) t: t-value (paired t-test); *: significance of the bias x-y (p < 0.05).
6) Determinations by EMIT adapted to an Eppendorf ACP 5040.
7) GC: Gas Chromatographie determination according to I.e. (1).
8) Orginal procedure peiiormed by use of an AutoLab 5000 System.
9) **: Not significant deviation from identity (t-test; p ^ 0.05).
creatine kinase 37 U/l (^ 70 U/l),
potassium 5.6mmol/l (3.6-5.4 mmol/1),
sodium 135 mmol/1 (132-155 mmol/1),
calcium 1.99 mmol/1 (2.15-2.60 mmol/1),
phosphate, inorganic 3.00 mmol/1 (0.83—1.67
mmol/1).
The phenytoin concentrations determined in sam-
ples of this patient by all of the immunoassays except
FPIA were much higher than those obtained by GC
(tab. 5). EMIT results differed by 22-85%, NIIA
by 68-114% and SLFIA constantly by about 50%,
whereas FPIA differed by only +1 to -7%. The er-
roneous results are probably not due to endogenous
compounds: When serum of an uraemic patient
(creatine: 1088 μπιοΐ/ΐ serum) was spiked with phe-
nytoin (final concentration: 59.5 μπιοΐ/ΐ) almost
identical results were obtained by EMIT and FPIA
(55.9 resp. 56.7 μιηοΐ/ΐ).
Free phenytoin
Free phenytoin was determined by EMIT, FPIA and
capillary GC. Free phenytoin was obtained by ultra-
filtration without loss by adsorption (11). When the
results of these methods were compared (tab. 6), an
acceptable agreement was demonstrated. As in
experiments with total phenytoin, however, evidence
was obtained that in the case of uraemia EMIT
yields erroneous results. In the case investigated, the
bias amounted to +109% s compared with capil-
lary GC (tab. 5). After addition of ammonium sul-
phate, extraction of the ultrafiltrate of the uraemic
patient by Chloroform and reconstitution of the dry
residue by a drug-free ultrafiltrate, the results ob-
tained by EMIT and FPIA agreed better (2.0 and
1.6μιηο1/1 respectively).




























































') %: Deviation in % s compared with GC.
2) N: Not determined; concentration below measuring r nge.
3) Lot L 03. 4) Lot 49551. s) Lot L 206015.
Specimen I: Before dialysis (creatinine: 988 μηιοΐ/ΐ serum).
Specimen II: After dialysis.
Specimen III: Before dialysis (creatinine: 1322 μηιοΐ/ΐ serum).
Lot 900 5032.
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Tab. 6. Comparison of the results obtained by various immunoassays and GC for the determination offree phenytoin in samples from














































') n: Number of contributing pairs of results.
2) sy.x: Standard error of residues.3) y: Mean value of method y.
4) x: Mean value of method x.
5) t: t-value (paired t-test); *: significance of the bias x-y (p ^ 0.05).
6) Original procedure performed by use of an AutoL b 5000 System.
7) **: significant deviation from identity (t-test: p ^ 0.05).
Specifici ty and interference
Cross-reactivity of substances with the immuno-
chemical determination of phenytoin is shown in ta-
ble 7. These compounds are structurally related to
phenytoin or. frequently applied concomitantly with
phenytoin. mong the compounds listed only the
phenytoin metabolite (5-(4-hydroxyphenyl)-5-phe-
nylhydantoin) showed a distinct interference.
The immunoassays were susceptible to iiiterfereiice
by extremely lipaemic sera (tab. 8). The interference
is most pronounced in EMIT and NIIA. With EMIT
all values differed by more than 10%, whereas the
Auto ICS rejected 3 out of 5 samples. Haemolysed
samples (haemoglobin ^ 7.7 g/l) or icteric samples
(bilirubin ^ 450 μιηοΐ/ΐ) were measured with ad^
equate ccur cy.


















































1) Determinations by EMIT adapted to an Eppendorf analyzer 5010. Lot Nr. LO3.
2) Lot Nr. 33-499 HQ.
3) Lot Nr. C 105013.
4) Lot Nr. 900 40 12.
5) Concentration of a compound added to drug-free pooled human serum, which is necessary to produce a quantitation error equivalent
to 20 μηηοΙ/1 phenytoin.
6) Concentration of a compound necessary to produce a quantitation error equivalent to 20 μπιοΐ/ΐ phenytoin in pooled human serum
containing 40 μπιοΐ/ΐ phenytoin.
Tab. 8. Interference by endogenous compounds with various immunoassays for the determination of phenytoin.































') Haemoglobin: 7.7 g/l.
2) Bilirubin: 450 μπιοΐ/ΐ.
3) Triglycerides: 7.7 mmol/1; cholesterol: 7.1 mmol/1.
4) Triglycerides: 13.4 mmol/1; cholesterol: 9.3 mmol/1.
5) Triglycerides: 18.8 mmol/1; cholesterol: 11.2 mmol/1.
6) Triglycerides: 23.3 mmol/1; cholesterol: 13.7 mmol/1.
7) Triglycerides: 30.9 mmol/1; cholesterol: 19,0 mmol/1.
8) Deviation in % from the target vajfue (39.(> uinol/l).
9) Samples rejected by ICS. *'
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Discussion
From the data presented it is concluded that all
methods evaluated are sufficiently precise and accu-
rate for monitoring total phenytoin concentrations in
the serum of nonuraemic patients. In uraemic pa-
tients treated with phenytoin, however, only FPIA
besides GC yielded reliable results for the determi-
nation of total and free phenytoin, s also shown by
Green et al. (12). There was no evidence of interfer-
ence in the immunoassays by endogenous com-
pounds accumulated in renal failure. The same con-
clusion was drawn by other authors (13,14,15) from
their experiments. Only Toseland et. al. (16) report-
ed a distinct interference in the EMIT-assay by
spiked uraemic sera. It seems more likely that the
erroneous results are due to some metabolites of
phenytoin that are accumulated in renal failure. In
uraemic patients the concentration of 5-(4-hydroxy-
phenyl)-5-phenylhydantoin-glucuronide (HPPH-
glucuronide) is 10 times higher (27—101 μπιοί) than
in nonuraemic patients (2.7—10.1 μιηοΐ/ΐ), whereas
the small concentrations of the unconjugated metab-
olite (0.1—0.8 μιηοΐ/ΐ) remain unaffected by renal
function (17).
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